Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lipella Pharmaceuticals, Inc. ( (LIPO) ) has shared an announcement.
On June 25, 2025, Lipella Pharmaceuticals announced its delisting from the Nasdaq Capital Market due to non-compliance with certain listing rules related to private placement transactions. Despite this setback, the company remains committed to relisting on a national exchange and continues its clinical programs unaffected. Lipella’s shares are currently traded on the OTC Pink Market, and the company is actively exploring relisting options to align with its strategic goals and deliver long-term value to stockholders.
The most recent analyst rating on (LIPO) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Lipella Pharmaceuticals, Inc. stock, see the LIPO Stock Forecast page.
More about Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on developing therapies for unmet medical needs. The company is advancing clinical programs for conditions such as oral lichen planus and hemorrhagic cystitis, supported by its in-house chemistry, manufacturing, and controls capabilities.
Average Trading Volume: 88,776
Technical Sentiment Signal: Sell
Current Market Cap: $4.91M
Find detailed analytics on LIPO stock on TipRanks’ Stock Analysis page.